Sunesis Pharmaceuticals (FRA:RYIS) EPS (Basic) : €-15.69 (TTM As of Dec. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals EPS (Basic)?

Sunesis Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Dec. 2020 was €-0.60. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2020 was €-15.69.

Sunesis Pharmaceuticals's EPS (Diluted) for the three months ended in Dec. 2020 was €-0.60. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 was €-15.69.

Sunesis Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2020 was €-0.60. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2020 was -15.69.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Sunesis Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Sunesis Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals EPS (Basic) Chart

Sunesis Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

EPS (Basic)

Get a 7-Day Free Trial

-281.04

-150.09

-80.76

-8.44

-4.40

Sunesis Pharmaceuticals Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
EPS (Basic)	Get a 7-Day Free Trial															-1.58	-5.54	-6.53	-3.02	-0.60

Sunesis Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Sunesis Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2020 is calculated as

Basic EPS (A: Dec. 2020 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-17.763	-	0)	/	4.027
	=	-4.41

Sunesis Pharmaceuticals's Basic EPS for the quarter that ended in Dec. 2020 is calculated as

Basic EPS (Q: Dec. 2020 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-3.951	-	0)	/	5.179
	=	-0.76

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was €-15.69

Sunesis Pharmaceuticals (FRA:RYIS) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Sunesis Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

http://www.sunesis.com

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines